Guduchi (Tinospora) for Blood Sugar

Guduchi, also called giloy, is Tinospora cordifolia, a climbing shrub that Ayurvedic medicine has used for many conditions, diabetes among them. A related but different species, Tinospora crispa, is used for diabetes in Southeast Asia and has its own research. The two are not interchangeable, so this page names the species each study used.

Evidence base: thin for blood sugar, and the best-documented human findings concern the liver. The research records behind this page hold no trial in people of guduchi given on its own for blood sugar. Two trials tested mixtures of five plants that included guduchi and reported lower blood sugar; a mixture cannot show what guduchi contributed. One randomized, placebo-controlled trial of Tinospora crispa found no significant change in blood sugar, and two of the patients taking it had marked rises in liver enzymes. Separately, hospital reports from India describe liver injury with autoimmune features in people taking Tinospora cordifolia: 6 patients in one case series and 43 patients in a study across 13 centers, where causality assessment rated the liver injury as probable in 67.4%.


Table of Contents

  1. What the Plant Is and How It Has Been Used
  2. Active Compounds and How They Act
  3. What Human Trials Found
  4. What Animal and Laboratory Studies Found
  5. Amounts Used in the Trials
  6. Safety Findings and Interactions
  7. Limits of the Evidence
  8. Key Research Papers
  9. Connections
  10. Featured Videos

What the Plant Is and How It Has Been Used

A 2023 review describes Tinospora cordifolia, known as guduchi or gurjo, as a herbaceous vine or climbing deciduous shrub of the family Menispermaceae, regarded as an important medicine in the Ayurvedic system and found in India, China, Myanmar, Bangladesh and Sri Lanka. The same review lists the ailments it has been used for: fevers, jaundice, diabetes, dysentery, urinary infections and skin diseases (PMID 37017881).

A 2017 review of the plant's chemistry adds that the whole plant is used in folk medicine and in Ayurveda, both alone and in combination with other plants (PMID 30428235).

A 2002 review of 45 Indian medicinal plants with anti-diabetic potential names Tinospora cordifolia among the plants most commonly studied in relation to diabetes (PMID 12020931).

A surge in use during the COVID-19 pandemic

Guduchi was promoted to the public in India as an immune booster to prevent coronavirus disease 2019 (COVID-19), according to a 2022 multicenter study (PMID 35037744). A 2023 review in an Ayurveda journal records that the Ministry of AYUSH of the Government of India recommended it for use in COVID-19 care (PMID 36400639). The Indian case series in the safety section come from that period.

Two species under similar names

Tinospora crispa belongs to the same plant family. A 2016 review describes it as widely distributed in Southeast Asia and the northeastern region of India, and states that traditional healers of Thailand, Malaysia, Guyana, Bangladesh and the southern Indian province of Kerala use it in the treatment of diabetes (PMID 26749336). A 2023 laboratory paper uses the name brotowali for it (PMID 37469648).

The 2023 Ayurveda review states that the authentic botanical source of guduchi is Tinospora cordifolia, and that Tinospora sinensis and Tinospora crispa are also commonly traded in the Indian subcontinent under the names guduchi or giloy (PMID 36400639). A name on a label is therefore not proof of which plant is inside. This site's page on how Tinospora species are told apart covers the identity question in detail.

What the records hold Tinospora cordifolia (guduchi, giloy) Tinospora crispa (brotowali)
Tradition of use Ayurveda and folk medicine of the Indian subcontinent Traditional healers in Thailand, Malaysia, Guyana, Bangladesh and Kerala
Human blood sugar trial of the plant alone None in the records One randomized, placebo-controlled trial: no significant change
Human blood sugar trials of mixtures Two trials of five-plant mixtures: lower blood sugar reported None in the records
Liver findings in people Case series of 6 and of 43 patients with liver injury showing autoimmune features, and a single case report Marked rise in liver enzymes in two patients in the randomized trial

Back to Table of Contents

Active Compounds and How They Act

Compounds found in guduchi

The 2017 chemistry review reports that four decades of research on Tinospora cordifolia have isolated alkaloids, sesquiterpenoids, diterpenoids, phenolics, steroids, aliphatic compounds and polysaccharides (long chains of sugar units), and lists a hypoglycemic, meaning blood-sugar-lowering, property among the pharmacological properties described for the plant. The same review states that although extracts and compounds have been studied both in the laboratory and in living organisms, only few mechanisms of action have been explored and they need further elaboration (PMID 30428235).

Pathways proposed by reviewers

A 2022 review proposes how the plant's compounds might act inside cells. Its authors write that they believe chemicals in Tinospora cordifolia may switch on the cell's own antioxidant enzymes, and that the plant is able to reduce an inflammation signal and to activate AMP-activated protein kinase (AMPK), an enzyme that senses a cell's energy supply, and sirtuins, a family of regulatory proteins (PMID 34509604). This is a review's reading of earlier reports. The abstract does not link any of these pathways to a measured change in blood sugar in people.

What has been reported for Tinospora crispa

The mechanism findings in the records are mostly for the other species. The 2016 review of Tinospora crispa reports that many diterpenes, triterpenes, phytosteroids, alkaloids and their glycosides have been isolated from it. It states that cell culture and animal studies suggest the herb stimulates the release of insulin from beta cells, the insulin-making cells of the pancreas, and that it causes a dose-dependent and time-dependent increase in glucose uptake in muscles (PMID 26749336).

In a laboratory enzyme test, an extract of Tinospora crispa stems inhibited alpha-glucosidase, an enzyme in the gut that splits starch and sugars into glucose (PMID 37469648).

Laboratory findings for Tinospora crispa set against the human trial result WHERE TINOSPORA CRISPA ACTED IN LABORATORY STUDIES Cell, animal and enzyme findings. None of these was shown in people. GUT Starch-splitting enzyme inhibited (enzyme test) PANCREAS More insulin released from beta cells (cells and animals) MUSCLE More glucose taken up (2016 review) IN PEOPLE: TINOSPORA CRISPA A 6-month randomized trial found no significant change in fasting glucose, hemoglobin A1C or insulin. IN PEOPLE: GUDUCHI (TINOSPORA CORDIFOLIA) No blood sugar trial of guduchi given alone is in the records.

Back to Table of Contents

What Human Trials Found

The records hold three human studies that measured blood sugar. None tested guduchi by itself. For each one, this section states what was compared with what.

Guduchi alone: no trial in the records

No record behind this page is a trial in which people took Tinospora cordifolia as the only test substance and had their blood sugar or hemoglobin A1C (HbA1c) measured. HbA1c is a blood test that reflects average blood sugar over roughly the previous three months.

A five-plant mixture in prediabetes (randomized, double-blind, placebo-controlled)

A 2019 randomized, double-blind, placebo-controlled trial tested a combination of five plants in people with prediabetes: Tinospora cordifolia, Indian kino tree (Pterocarpus marsupium), gymnema (Gymnema sylvestre), ginger (Zingiber officinale) and bitter melon (Momordica charantia). One group took the mixture together with lifestyle management; the other took a placebo together with lifestyle management (PMID 30661947).

This is a result for a five-plant mixture taken alongside lifestyle changes. The trial had no group that took guduchi alone, and the abstract gives no figures for the size of the changes in glucose or HbA1c.

A five-plant mixture in type 2 diabetes (8 weeks)

A 2014 study gave a different five-plant combination to people with type 2 diabetes: salacia (Salacia oblonga), Tinospora cordifolia, Indian gooseberry (Emblica officinalis), turmeric (Curcuma longa) and gymnema (Gymnema sylvestre) (PMID 24976431).

PubMed indexes this paper as a randomized controlled trial. The abstract describes patients with diabetes and a group of healthy volunteers; it does not describe a placebo group of people with diabetes, and it gives no figures for the size of the changes. The authors describe the study as short-term and call for study of the long-term effect in larger populations.

Tinospora crispa added to diabetes drugs (randomized, double-blind, placebo-controlled): no effect

A 2004 randomized, double-blind, placebo-controlled trial tested the related species, Tinospora crispa, as an additional treatment in patients with type 2 diabetes who had not responded to oral blood-sugar-lowering drugs and had refused insulin injection (PMID 15222526).

The trial's authors concluded that there is no evidence to support the use of Tinospora crispa at 3 grams a day as additional therapy in patients with type 2 diabetes who did not respond to oral blood-sugar-lowering drugs, and that patients receiving it may have an increased risk of liver dysfunction. This is a negative result: the herb did not lower blood sugar, and it was followed by a liver finding.

Back to Table of Contents

What Animal and Laboratory Studies Found

Everything in this section comes from animals, cells or enzyme tests, or from reviews that summarise such work. None of it is a finding in people.

Guduchi (Tinospora cordifolia)

Tinospora crispa

Set beside the human trial above, the Tinospora crispa record is a clear example of a laboratory signal that did not carry over: the animal and cell work pointed to more insulin and lower glucose, and the 6-month randomized trial in people found no significant change in either.

Back to Table of Contents

Amounts Used in the Trials

The table lists what the researchers gave in each human study. These are records of what was tested. They are not doses for the reader.

Study Who took part What was given Amount Length
Randomized, double-blind, placebo-controlled trial, 2019 114 people with prediabetes, 57 in each group Five-plant mixture that included Tinospora cordifolia, with lifestyle management 2 g per day of the mixture 6 months
Study indexed as a randomized controlled trial, 2014 89 patients with type 2 diabetes; 50 healthy volunteers Five-plant mixture that included Tinospora cordifolia 1000 mg per day of the mixture 8 weeks
Randomized, double-blind, placebo-controlled trial, 2004 Patients with type 2 diabetes not responding to oral drugs: 20 on the herb, 20 on placebo Tinospora crispa powder in capsules, added to existing treatment 1 gram three times daily 6 months

Neither mixture abstract states how much of the daily amount was guduchi.

Back to Table of Contents

Safety Findings and Interactions

Liver injury reported in people taking Tinospora cordifolia

Case series, 2021 (6 patients). Over a study period of 4 months during the COVID-19 pandemic, six patients (4 women, 2 men) with a median age of 55 years and a history of Tinospora cordifolia use presented with symptoms of acute hepatitis (PMID 34230786).

The authors wrote that Tinospora cordifolia seems to induce an autoimmune-like hepatitis or to unmask an underlying autoimmune chronic liver disease, and they recommended caution in its use, especially in people predisposed to autoimmune disorders.

Multicenter study, 2022 (43 patients). A retrospective study spanning 13 centers at nine locations in India collected cases of liver injury that followed giloy use (PMID 35037744).

The authors concluded that giloy is associated with acute hepatitis with autoimmune features and can unmask autoimmune hepatitis in people with silent chronic liver disease related to it.

Case report, 2023 (1 patient). A 50-year-old woman with a history of Hashimoto thyroiditis developed abdominal discomfort and nausea of two weeks' duration, which coincided with starting a supplement containing Tinospora cordifolia. Blood tests showed severely elevated transaminases (liver enzymes), while viral panels, autoimmune blood tests and imaging were unremarkable. The Roussel Uclaf causality assessment method score was 6, indicating probable drug-induced or herb-induced liver injury. The supplement was stopped and she took a three-day course of oral steroids. The transaminases fell by more than 50% within two weeks of stopping and returned to baseline within three months (PMID 37273324).

Acute hepatitis typically shows as tiredness, loss of appetite, nausea, discomfort under the right ribs, dark urine and yellowing of the skin and eyes (jaundice).

How liver specialists classify the reports

A 2022 systematic analysis of published reports of drug-induced autoimmune-like hepatitis identified 186 case reports, 148 for conventional drugs and 38 for herbal and dietary supplements. It found that Tinospora cordifolia and khat were the only herbal and dietary supplements with probable cases (PMID 35596597).

A 2023 expert meeting report from two international liver research groups lists Tinospora cordifolia among the more than 40 drugs and supplements implicated in this kind of liver injury. The report states that the injury can be indistinguishable from autoimmune hepatitis in laboratory and biopsy features, that it often resolves on its own after the implicated substance is withdrawn and rarely requires long-term immune-suppressing treatment, whereas autoimmune hepatitis mostly does require it, and that there is no specific marker that allows a precise diagnosis (PMID 37164270).

The published dispute over which plant was taken

The liver reports have been contested in print. A 2023 review in an Ayurveda journal examined the six-patient case series and noted that patient histories and the products taken varied from case to case, and that the botanical authenticity of the products was not investigated in that series. Its authors state that Tinospora crispa is known to cause liver toxicity, judge it unlikely that authentic Tinospora cordifolia induced the hepatitis, and think it probable that a wrong species was taken. They add that the case series highlights the serious issue of adulteration in herbal markets (PMID 36400639). A 2024 essay makes a similar argument, attributing the observed harms to Tinospora crispa, which resembles Tinospora cordifolia in appearance (PMID 36803756).

Both papers offer the wrong-species explanation as a judgement. Neither abstract reports a test of what the patients had taken. For a person buying a product, the two explanations lead to the same place: either authentic guduchi can injure the liver in some people, or products sold as guduchi sometimes contain a relative that does. This site's pages on the autoimmune hepatitis reports and on species identity and adulteration set out the reports, the objections and the later testing of patients' samples.

Liver and other findings with Tinospora crispa

The 2004 randomized trial findings are given above: marked elevation of liver enzymes in two patients, reversed on stopping, with a rise in cholesterol and a weight reduction in the group taking the herb (PMID 15222526). The 2016 review of the species refers to its reported liver toxicity and states that the herb may be used with caution in view of it (PMID 26749336).

What the mixture trials recorded

In the 8-week study of a five-plant mixture in type 2 diabetes, the researchers measured two liver enzymes (alkaline phosphatase and alanine aminotransferase) and two kidney markers (blood urea nitrogen and creatinine) and found an insignificant change compared with control (PMID 24976431). In the 6-month prediabetes trial, no adverse effects were reported by any participant (PMID 30661947). A 2022 review states that the safety profile of Tinospora cordifolia was confirmed in a toxicological analysis; its abstract does not mention the liver injury reports (PMID 34509604).

Trials of this size are too small to detect an uncommon reaction. The 2023 case report describes the liver injury as appearing idiosyncratic, meaning it arises in a small share of users and not in proportion to the amount taken (PMID 37273324).

Low blood sugar with glucose-lowering drugs

Anything that lowers blood sugar adds to the effect of insulin and sulfonylurea drugs, and low blood sugar (hypoglycemia) results when the combined effect is too large. The signs of low blood sugar are shakiness, sweating, fast heartbeat and confusion, and at lower levels seizure or loss of consciousness. The records behind this page hold no report of hypoglycemia with guduchi and no trial designed to look for it. In the one trial that added a Tinospora species to diabetes drugs, the Tinospora crispa trial, blood sugar did not change.

Type 1 diabetes

Type 1 diabetes is a state of absolute insulin deficiency. No herb, food or diet replaces insulin; without insulin, diabetic ketoacidosis develops, and it is fatal if untreated. None of the studies on this page enrolled people with type 1 diabetes.

Products differ, and some groups were not studied

Back to Table of Contents

Limits of the Evidence

Taken together: for blood sugar, guduchi rests on tradition, on laboratory and animal work, and on two trials of mixtures. For the liver, there are published patient series with numbers. The human evidence of harm is better documented than the human evidence of benefit.

Back to Table of Contents

Key Research Papers

  1. Sangsuwan C, Udompanthurak S, Vannasaeng S, Thamlikitkul V. Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus. J Med Assoc Thai. 2004;87(5):543-6. PubMed PMID: 15222526
  2. Nakanekar A, Kohli K, Tatke P. Ayurvedic polyherbal combination (PDBT) for prediabetes: A randomized double blind placebo controlled study. J Ayurveda Integr Med. 2019;10(4):284-289. PubMed PMID: 30661947
  3. Kurian GA, Manjusha V, Nair SS, Varghese T, Padikkala J. Short-term effect of G-400, polyherbal formulation in the management of hyperglycemia and hyperlipidemia conditions in patients with type 2 diabetes mellitus. Nutrition. 2014;30(10):1158-64. PubMed PMID: 24976431
  4. Kulkarni AV, Hanchanale P, Prakash V, Kalal C, Sharma M, Kumar K, et al. Tinospora Cordifolia (Giloy)-Induced Liver Injury During the COVID-19 Pandemic-Multicenter Nationwide Study From India. Hepatol Commun. 2022;6(6):1289-1300. PubMed PMID: 35037744
  5. Nagral A, Adhyaru K, Rudra OS, Gharat A, Bhandare S. Herbal Immune Booster-Induced Liver Injury in the COVID-19 Pandemic - A Case Series. J Clin Exp Hepatol. 2021;11(6):732-738. PubMed PMID: 34230786
  6. Nnamani I, Tolu-Akinnawo O, Dufera RR, Akintunde A, Maliakkal B. Tinospora cordifolia (Guduchi/Giloy)-Induced Liver Injury: A Case Review. Cureus. 2023;15(5):e39793. PubMed PMID: 37273324
  7. Björnsson ES, Medina-Caliz I, Andrade RJ, Lucena MI. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895-1909. PubMed PMID: 35596597
  8. Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023;79(3):853-866. PubMed PMID: 37164270
  9. Panneer Selvam K, Payyappallimana U, Ravikumar K, Venkatasubramanian P. Can Guduchi (Tinospora cordifolia), a well-known ayurvedic hepato-protectant cause liver damage? J Ayurveda Integr Med. 2023;14(1):100658. PubMed PMID: 36400639
  10. Singh PA, Bajwa N. Is Tinospora cordifolia Responsible for Drug-induced Liver Injury? Curr Drug Saf. 2024;19(1):8-10. PubMed PMID: 36803756
  11. Thomas A, Rajesh EK, Kumar DS. The Significance of Tinospora crispa in Treatment of Diabetes Mellitus. Phytother Res. 2016;30(3):357-66. PubMed PMID: 26749336
  12. Kusriani H, Susilawati E, Nurafipah L, Nurkholifah. Antidiabetic Activity of Combination of Binahong (Anredera cordifolia Ten. Steenis), Cherry (Muntingia calabura L.) and Brotowali (Tinospora crispa L.) Extracts. J Pharm Bioallied Sci. 2023;15(2):75-80. PubMed PMID: 37469648
  13. Arunachalam K, Yang X, San TT. Tinospora cordifolia (Willd.) Miers: Protection mechanisms and strategies against oxidative stress-related diseases. J Ethnopharmacol. 2022;283:114540. PubMed PMID: 34509604
  14. Singh D, Chaudhuri PK. Chemistry and Pharmacology of Tinospora cordifolia. Nat Prod Commun. 2017;12(2):299-308. PubMed PMID: 30428235
  15. Ahsan R, Mishra A, Badar B, Owais M, Mishra V. Therapeutic Application, Phytoactives and Pharmacology of Tinospora cordifolia: An Evocative Review. Chin J Integr Med. 2023;29(6):549-555. PubMed PMID: 37017881
  16. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol. 2002;81(1):81-100. PubMed PMID: 12020931

PubMed Topic Searches

  1. PubMed: Tinospora cordifolia and type 2 diabetes clinical trials
  2. PubMed: Tinospora crispa randomized trials in type 2 diabetes
  3. PubMed: Tinospora cordifolia and liver injury
  4. PubMed: Tinospora cordifolia and autoimmune hepatitis

Back to Table of Contents

Connections

Back to Table of Contents